At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223.
JanusN, Launay-VacherV, ThyssA, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol. 2013;24(2):501-7. [PMID:23038759] [https://doi.org/10.1093/annonc/mds344].
JanusN, Launay-VacherV, DerayG, ThyssA, ThariatJ. Management of chemotherapy in hemodialysis patients. Bull Cancer. 2012;99(3):371-80. [PMID:22133734]
HocheggerK, LhottaK, MayerG, CzejkaM, HilbeW. Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant. 2007;22(1):289-90. [PMID:16935890] [https://doi.org/10.1093/ndt/gfl498].
ItoH, InamuraS, TagaM, et al. A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone. Gan To Kagaku Ryoho. 2013;40(9):1245-7. [PMID:24047790]
TsangES, de HaanM, EiglBJ. A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. J Oncol Pharm Pract. 2017:1. [PMID:28147927]
NguyenNC, ShahM, ApplemanLJ, ParikhR, MountzJM. Radium-223 therapy for patients with metastatic castrate-resistant prostate cancer: an update on literature with case presentation. Int J Mol Imaging. 2016;2016:1. [PMID:27774318] [https://doi.org/10.1155/2016/2568031].
SartorO, ColemanRE, NilssonS, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090-7. [PMID:28453701] [https://doi.org/10.1093/annonc/mdx044].
KeizmanD, FosboelMO, ReicheggerH, et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multi- center database. Prostate Cancer Prostatic Dis. 2017;20(3):289-93. [PMID:28244493] [https://doi.org/10.1038/pcan.2017.6].